Cannabis Science Inc. Cannabis Science Inc.
Cannabis Science Inc. Cannabis Science Inc.
  • Home
  • About Us
    • Corporate Overview
    • Mission Statement
    • Cannabis Science Team
    • Careers & Corporate Culture
  • iCannabinoid
    • Join Now!
  • R&D
    • The Science of Cannabinoids
    • CBIS Cannabinoid Research
    • Critical Ailments
  • COLLABORATIONS & PROJECTS
    • CBIS Medical Consortium
    • Global Economic Development
    • Pan African A & C University
    •     African Economic Initiative
    • American States University
    •     North American Economic Initiative
    • Dana-Farber
    • CFA
    • Stellenbosch University
    • CBIS Bottle It
  • Products & Pharmacies
    • Products
    • Order Online
    • Pharmacies
  • Investors
    • CBIS Current Share Structure
    • SEC Filings
  • Media
    • CBIS News Releases
    • CBIS In The News
    • CBIS Events
  • Contact

latest Articles

  • Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth
  • Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements
  • Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions
  • Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally
  • Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations

  1. Home

Total: 448 results found.

Page 7 of 23

Cannabis Science Recaps "Your Money's Worth" Radio Interview: The Company Spoke of Its Market Prioritization, Progress to-Date, and Strategic Planning Moving Forward

Created on 2018-06-13 18:53:45

Analyst Initiates Coverage on Cannabis Science w/ Accumulate Recommendation and $0.10 PPS Target as Company Advances Additional Product Lines in California and Gears Up for Animal Healthcare Entry Through Equi-Pharm

Created on 2018-06-13 18:52:19

Cannabis Science (CBIS) Announces Positive Results in California Test Run of Its Pure Decarboxylated CO2 Oil (PDCO) Released Through the Cannabis Science Research Foundation (CSRF) to 15 Dispensaries & Several Less Fortunate, Self-Medicating Patients for

Created on 2018-06-13 18:51:22

Cannabis Science Releases Cannabinoid-Formulated Capsule Product Line in California; Initial Capsule Formulations Released Are CBD, Indica, and Sativa

Created on 2018-06-13 18:50:30

Cannabis Science Enters Select, New High-Dosage Product Line of CBD, Sativa, and Indica Capsules Into the Industry-Famous Emerald Cup Event This Weekend in Santa Rosa, CA

Created on 2018-06-13 18:47:22

After Successful Formulation Work, Cannabis Science Follows Through With a Full Clinical Drug Development Agreement With ImmunoClin to Deliver GMP Quality Pre-Clinical Data to Enter CS-NEURO-1 Into a Phase I Human Study in Europe

Created on 2018-06-13 18:40:09

After Successful Formulation Work, Cannabis Science Follows Through With a Full Clinical Drug Development Agreement With ImmunoClin to Deliver GMP Quality Pre-Clinical Data to Enter CS-NEURO-1 Into a Phase I Human Study in Europe

Created on 2018-06-13 18:39:06

Cannabis Science (OTC PINK: CBIS) to Be a Featured Guest on "Your Money's Worth" National Radio Show, Tonight From 5-7 PM (EST) on 1470 AM, WWNN Radio South Florida, as Well as Live Internet Streaming

Created on 2018-06-13 18:38:05

Cannabis Science Releases Forward-Looking Clinical Guidance for 2016; the Company Is Positioned to Expand Clinical Trials Into the New Year

Created on 2018-06-13 18:33:26

Cannabis Science Announces Update on Issuance of Dividends

Created on 2018-06-13 18:27:58

Cannabis Science Announces Update on Issuance of Dividends

Created on 2018-06-13 18:26:02

CBIS & Purple Haze Properties Launch "Jimi's Meds" eCommerce Website Powered by Cannabis Science and Showcased This Weekend at the High Times Cannabis Cup in Southern California

Created on 2018-06-12 23:15:48

Cannabis Science Targets Successful Autism Treatments and Brings Family Autism Advocate Mieko Hester-Perez on Its Scientific Advisory Board

Created on 2018-06-12 23:14:49

Purple Haze Properties (PHP) & Cannabis Science (CBIS) Announce Successful Launch of Hendrix-Themed Cannabis Theraputic Products

Created on 2018-06-12 23:13:41

CBIS Set to Partner and Power the New iPhone APP, "The Joey Network", Just Released by Mieko Hester-Perez, SAB Member, Providing Patients and Families a Wealth of Autism Resources and Cannabis Treatment Options

Created on 2018-06-12 23:12:29

In an Unprecedented Move, Cannabis Science President & CEO, Mr. Raymond C. Dabney, to Gift His Personal Shares to Shareholders to Replace Both Previously Announced Dividends, to Personally Complete Promised Payouts

Created on 2018-06-12 23:11:36

Cannabis Science CEO Plans to Expand Share Gifts to ALL Shareholders up to March 31, 2016, Thus Including ALL Old & New Shareholders up to the New Cutoff Date; Issues Preliminary Instructions for Shareholders of Record Dates to Receive Gifted Shares

Created on 2018-06-12 23:10:23

Cannabis Science Moves Forward Clinical Drug Development With Confidence as GW Pharma Announces Positive Results With Its CBD-Based Epilepsy Formulation

Created on 2018-06-12 23:09:31

Positive Cannabinoid Testing Data in California Prompts Cannabis Science Lab Expansions for IGXBio's GenePro FDA Investigational New Drug (IND) Number 015982 for Further Drug Development to Identify & Develop Agonist Cannabinoids for GenePro

Created on 2018-06-12 23:08:28

Cannabis Science Negotiates a Total 360,000 Sq. Ft. Licensed Cannabinoid Grow and Formulation Processing in Nevada, Including Facilities for Educational and Medical Clinic and Laboratory for Drug Development Programs Targeting Multiple Critical Ailments

Created on 2018-06-12 23:07:31

  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End
REACH US.

2019 US Federal Contractor

DUNS number: 830406356
CAGE code: 5FZM9

NAICS Codes selected:

541711 - Research and Development in Biotechnology

621511 - Medical Laboratories

624230 - Emergency And Other Relief Services

Contact.

Cannabis Science Inc.

Mr. Raymond C. Dabney
President & CEO

raymond.dabney@cannabisscience.com



 
 
Copyright © 2019 Cannabis Science Inc. All Rights Reserved.